Structure-activity relationships of novel hematoregulatory peptides

Journal of Medicinal Chemistry

Volumn 39, Issue 19, 1996, Pages 3814-3819

  Bhatnagar, Pradip K ^a   Agner, Erik K ^b   Alberts, Doreen ^a   Arbo, Bente E ^b   Callahan, James F ^a   Cuthbertson, Allan S ^b   Engelsen, Steinar J ^c   Fjerdingstad, Hege ^b   Hartmann, Michael ^c   Heerding, Dirk ^a   Hiebl, Johann ^c   Huffman, William F ^a   Hysben, Mette ^b   King, Andrew G ^a   Kremminger, Peter ^c   Kwon, Chet ^a   LoCastro, Steve ^a   Løvhaug, Dagfinn ^b   Pelus, Louis M ^a   Petteway, Steve ^a,d   Takata, Joanne S ^a   more..

^a GLAXOSMITHKLINE   (United Kingdom)

^b ALTANA PHARMA AG   (Germany)

^c Nycomed Holdings AS   (Austria)

^d CATO RESEARCH LTD   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLONY STIMULATING FACTOR; GLASPIMOD; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; COLONY FORMATION; DOSE RESPONSE; HOST RESISTANCE; MOUSE; NONHUMAN; PEPTIDE SYNTHESIS; STROMA CELL; STRUCTURE ACTIVITY RELATION;

AMINO ACID SEQUENCE; ANIMALS; BONE MARROW CELLS; CELL LINE; COLONY-FORMING UNITS ASSAY; DOSE-RESPONSE RELATIONSHIP, DRUG; HEMATOPOIESIS; HEMATOPOIETIC CELL GROWTH FACTORS; HEMATOPOIETIC STEM CELLS; MICE; MICE, INBRED BALB C; MOLECULAR STRUCTURE; OLIGOPEPTIDES; PICOLINIC ACIDS; STROMAL CELLS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 9544246724     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm960099d     Document Type: Article

References (33)

1. Rich, I. N. Hematopoietic-Initiating Cells. J. Perinat. Med. 1995, 23, 31-38.
2. Ratajczak, M. Z.; Gewirtz, A. M. The Biology Of Hematopoietic Stem-Cells. Semin. Oncol. 1995, 22, 210-217.
3. Wickenhauser, C.; Thiele, J. Cytokines And Hematopoiesis. Pathology. 1995, 16, 181-191.
4. Metcalf, D. The Colony Stimulating Factors: Discovery, Development and Clinical Applications. Cancer 1990, 65, 2185-2195.
5. Moore, M. A. S. Hematopoietic Growth Factor Interactions: In Vitro and In vivo Preclinical Evaluation. Cancer Surv. 1990, 9, 7-80.
6. Demetri, G. D. Hematopoietic Growth Factors: Current Knowledge, Future Prospect. Curr. Prob. Cancer 1992, 16, 177-259.
7. Quesniaux, V. F. J. Interleukin 9, 10, 11 and 12 and Kit Ligand: A Brief Review. Res. Immunol. 1992, 143, 385-400
8. Dale, D. C. Hematopoietic Growth For the Treatment of Severe Chronic Neutropenia. Stem Cells 1995, 13, 94-100.
9. Hansen, F. Hematopoietic Growth And Inhibitory Factors In Treatment Of Malignancies - A Review. Acta Oncol. 1995, 34, 453-468.
10. Hartung, T.; Volk, H. D.; Wendel, A. G-CSF - An Antiinflammatory Cytokine. J. Endotoxin Res. 1995, 2, 195-201.
11. Paukovits, W. R.; Laerum, O. D. Structural Investigation on a Peptide Regulating Hemopoiesis In Vitro and In Vivo. Hoppe-Seylers Z. Physiol. Chem. 1984, 365, 303-311.
12. Laerum, O. D.; Sletvold, O.; Bjerknes, R.; Eriksen, J. A.; Johansen, J. H.; Schanche, J. S.; Tveteras, T.; Paukovits, W. R. The Dimer of Hematoregulatory Peptide (HP5b) Stimulates Mouse and Human Myelopoiesis In Vitro. Exp. Hematol. 1988, 16, 274-280.
13. Alberts, D. P.; Agner, E.; Silvestri, J. S.; Kwon, C.; Newlander, K.; King, A. G.; Pelus, L. M.; DeMarsh, P. L.; Frey, C.; Petteway, S. R.; Huffman, W. F.; Bhatnagar, P. K. Synthesis of a Novel Hematopoietic Peptide SK&F 107647. Thirteenth Am. Pept. Symp. 1993, 367-359.
14. Pelus, L. M.; King, A. G.; Broxmeyer, H. E.; DeMarsh, P. L.; Petteway, S. R.; Bhatnagar, P. K. In-vivo Modulation of Hematopoiesis by a Novel Hematoregulatory Peptide. Exp. Hematol. 1993, 22, 239-247.
15. Frey, C. L.; DeMarsh, P. L.; Sucoloski, S. K.; Bhatnagar, P. K.; Pelus, L. M. The Effect of the Hematoregulatory Peptide SK&F 107647 on Murine Peritoneal Macrophage Anti Candida Activity. 31st Intersci. Conf. Antimicrob. Agents Chemother. 1991, p113.
16. DeMarsh, P. L.; Sucoloski, S. K.; Frey, C. L.; Koltin, Y.; Actor, P.; Bhatnagar, P. K.; Petteway, S. R. Efficacy of the Hematoregulatory Peptide SK&F 107647 in Experimental Systemic Candida Albicans Infections in Normal and Immunesuppressed Mice. Immunopharmacology 1994, 27, 199-206.
17. DeMarsh, P. L.; Wells, G. I.; Lewandowski, T. F.; Bhatnagar, P. K.; Ostovic, E. J. Treatment of Experimental Gram-negative and Gram-positive Bacterial Sepsis with the Hematoregulatory Peptide SK&F 107647. J. Infect. Dis. 1995, in press.
18. Vieby, O. P.; Olsen, W. M. Accelerated Hematopoietic Recovery with the Hematoregulatory Peptide Dimer SK&F 107647 in Bone Marrow Transplantation. Bone Marrow Transplant 1995, 12, 305-311.
19. Pelus, L. M.; DeMarsh, P. L.; King, A.; Frey, C.; Bhatnagar, P. K. Novel Hematoregulatory Peptides: Monomeric and Dimeric Forms Determine Opposite Biological Activity. In The Negative Regulation of Hematopoiesis: From Fundamental Aspects to Clinical Applications; Guigon, M., Lemoine, F. M., Daniak, N., Schechter, A., Najman, A., Eds.; J Libbey Eurotext: Paris, 1993; pp 193-200.
20. Stewart, J. M.; Young, J. D. Solid Phase Peptide Synthesis, 2nd ed.; Pierce Chemical Co.: Rockford, IL, 1984.
21. Bodansky, M.; Bodansky, A. The Practice of Peptide Synthesis; Springer-Verlag: Berlin, 1984.
22. Nutt, R.; Strachan, R.; Veber, D.; Holly, F. J. Useful Intermediates for Synthesis of Dicarba Analogues of Cystine Peptides: Selectively Protected α-Aminosuberic Acid and α,α-Diamino-suberic Acid of Defined Stereochemistry. J. Org. Chem. 1980, 45, 3078-3080.
23. Schöllkopf, U.; Neubauer, J. Asymmetric Synthesis via Heterocyclic Intermediates: XII Enantioselective Synthesis of (R)-α-Amino Acids Using tert-Leucine as Chiral Auxiliary. Synthesis 1982, 11, 861-864.
24. King, A. G.; Bhatnagar, P. K.; Balcarek, J.; Pelus, L. M. Modulation of Bone Marrow Stromal Cell Production of Colony Stimulating Activity by the Synthetic Peptide, SK&F 107647. Exp. Hematol. 1991, 19, 481.
25. Heyworth, C. M.; Spooncer, E. In vitro Clonal Assays For Murine Multipotential and Lineage Restricted Myeloid Progenitor Cells. In Hematopoiesis A Practical Approach; Teasta, N. G., Molineux, G., Eds.; IRL Press: Oxford, U.K., 1993; pp 37-71.
26. The extreme potency of 1 complicates the interpretation of these results. These analogues may be devoid of activity since one cannot rule out the possibility that the observed (diminished) activity may result from a minor contamination of 1.
27. Substitution of cyclopentanecarboxylic acid, 2-furoic acid, 3-furoic acid, 5-oxo-2-tetrahydrofurancarboxylic acid, 2-oxo-4-thiazolidenecarboxylic acid, 2-tetrahydrofurancarboxylic acid, 3-tetrahydrofurancarboxylic acid, 2- thiophenecarboxylic acid, 3-thiophenecarboxylic acid, tyrosine, and pyridineacetic acid at position 1 of 1 results in analogues that are inactive at the highest dose tested (1 μg/mL).
28. Substitution of bicyclic carboxylic acids, e.g., 4-hydroxyquinoline-2-carboxylic acid, indole-2-carboxylic acid, 1-isoquinolinecarboxylic acid, 3- isoquinolinecarboxylic acid, and qunioline-2-carboxylic acid, at position 1 of 15 yielded analogues that were inactive at the highest dose (1 μg/mL) tested.
29. Synthesis of (2S,8S)-diaminoazelaic acid and (2S,9S)-diaminosebacic acid are reported in PCT WO 93/24523.
30. 5 with Ala, Asp, Glu, 4-amino-L-phenylalanine, (2S)-2,4-diaminobutyric acid (Dba), and 1,6-diaminohexane (Dhe) yielded analogues that were inactive at the highest dose (1 μg/mL) tested.
31. Watson, S. W.; Levin, J.; Novitsky, T. J. Endotoxins and Their Detection with the Limulus Amebocyte Lysate Test. 1982.
32. The commercial kit for endotoxin testing was purchased from Associate of Cape Cod, Inc., MA.
33. HF is a highly toxic, low-boiling (bp 19 °C) corrosive acid. A Teflon apparatus (available commercially) must be used for cleavage reactions.